Parkinson’s disease management strategies

References

• Duvoisin RC, Golbe LI. Toward a definition of parkinson’s disease. Neurology 39, 746 (1989).
   PubMed Web of Science ®Google Scholar
• Goetz CG. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord. 20 (5), 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson’s disease. Expert Opin. Pharmacother. 4(10), 1747–1761 (2003).
   PubMed Web of Science ®Google Scholar
• Poewe W, Granata R, Geser F. Pharmacologic treatment of Parkinson’s disease. In: Movement Disorders: Neurologic Principles and Practice. Watts RL, Koller WC (Eds). Movement McGraw-Hill, NY, USA, 247–271 (2004).
   Google Scholar
• Ehringer H, Hornykiewicz O. Distribution of norepinephrine and dopamine (3-hydroxytyramine) in human brain: their behaviour in extrapyramidal system diseases. Klin Wochenschr. 38, 1236–1239 (1960).
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of L-3,4-dihydroxyphenylalanine ( = L-DOPA) on akinesia in parkinsonism. Wien. Klin. Wochenschr. 73(45), 787–788 (1961).
   PubMedGoogle Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N. Engl. J. Med. 276, 374–379 (1967).
   PubMed Web of Science ®Google Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R, and the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 53, 1012–1019 (1999).
   PubMed Web of Science ®Google Scholar
• The Global Parkinson’sdisease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov. Disord. 17(1), 60–67 (2002).
   PubMedGoogle Scholar
• Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord. 19(9), 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Schwarz C, Larrosa O, de la Llave Y, Garcia De Yebenes J. L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. Neurology 61, 1008–1010 (2003).
   PubMedGoogle Scholar
• Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 43(Suppl. 6), S23–S27 (1993).
   PubMedGoogle Scholar
• Rajput AH, Fenton ME, Birdi S et al. Clinical-pathological study of levodopa complications. Mov. Disord. 17(2), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat. Disord. 10, 221–226 (2004).
   PubMedGoogle Scholar
• Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321, 1364–1371 (1989).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov. Disord. 12(5), 634–638 (1997).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Oakes D, Fahn S et al. Impact of sustained deprenyl (selegiline) in levodopa-treated parkinson’s disease: A randomized placebo-controlled extension of the deprenyl and tocopherol anti-oxidative therapy of parkinsonism trial. Ann. Neurol. 51, 604–612 (2002).
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early parkinson’s disease patients. Mov. Disord. 19(8), 916–923 (2004).
   PubMedGoogle Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with parkinson’s disease and motor fluctuations. Arch. Neurol. 62, 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke CE. A ‘cure’ for Parkinson’s disease: can neuroprotection be proven with current trial designs? Mov. Disord. 19(5), 491–498 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can. Med. Assoc. J. 129, 974–975 (1983).
   PubMed Web of Science ®Google Scholar
• Uitti RJ, Rajput AH, Ahlskog JE et al. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46, 1551–1556 (1996).
   PubMedGoogle Scholar
• Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. Letter to Editor–New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov. Disord. 13(5), 851 (1998).
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5), 1323–1326 (1998).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Dhawan V. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov. Disord. 19(12), 1522–1523 (2004).
   PubMedGoogle Scholar
• Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology 63, 301–304 (2004).
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson’s disease. Arch. Neurol. (2005)(In Press)
   PubMedGoogle Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease. a randomized controlled trial. JAMA 284, 1931–1938. (2000)
   PubMed Web of Science ®Google Scholar
• Holloway R, Shoulson I, Fahn S et al. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a 4-year randomized controlled trial. Arch. Neurol. 61(7), 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Katzenschlager R, Head J, Ben-Schlomo Y, on behalf of the Parkinson’s disease research group of the United Kingdom. Ten-year follow-up of three different initial treatments in de-novo PD. A randomized trial. Neurology 57, 1687–1694. (2001)
   PubMed Web of Science ®Google Scholar
• Rajput AH, Uitti RJ, Rajput AH, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson’s disease. Parkinsonism Relat. Disord. 3(3), 159–165 (1997).
   PubMedGoogle Scholar
• Rajput AH. The protective role of levodopa in the human substantia nigra. In: Parkinson’s disease: Advances in Neurology. Calne D, Calne S, (Eds). Lippincott Williams & Wilkins, PA, USA 327–336 (2001).
   Google Scholar
• Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat. Disord. 8, 95–100 (2001).
   PubMed Web of Science ®Google Scholar
• Baba Y, Wharen RE Jr, Uitti RJ. Parkinson’s disease: surgical treatment - stereotactic procedures. In: Parkinson’s disease. Ebadi M, Pfeiffer RF (Eds). CRC Press, FL, USA, 745–765 (2005).
   Google Scholar
• Okun MS, Vitek JL. Lesion therapy for Parkinson’s disease and other movement disorders: update and controversies. Mov. Disord. 19(4), 375–389 (2004).
   PubMed Web of Science ®Google Scholar
• Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund H-J. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Ann. Neurol. 55, 871–875 (2004).
   PubMed Web of Science ®Google Scholar
• Russmann H, Ghika J, Combrement P et al. L-Dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. Neurology 63, 153–155 (2004).
   PubMedGoogle Scholar
• Russmann H, Ghika J, Villemure J-G et al. Subthalamic nucleus deep brain stimulation in Parkinson’s disease patients over age 70 years. Neurology 63, 1952–1954 (2004).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Stern W, Laverty WH. Chronic low dose therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34(8), 991–996 (1984).
   PubMedGoogle Scholar
• Lang AE, Lozano AM. Parkinson’s disease–second of two parts. N. Engl. J. Med. 339, 1130–1143 (1998).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Recent Developments in Parkinson’s Disease. Fahn S, Marsden CD, Calne D, Goldstein M, (Eds). Macmillan Healthcare Information, N.J, USA 153–305 (1987).
   Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 17, 427–442 (1967).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow-up. J. Neurol. Neurosurg. Psychiatr. 57, 1034–1038 (1994).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin. Neuropharmacol. 13(6), 553–558 (1990).
   PubMed Web of Science ®Google Scholar
• Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: A review of two interconnected, episodic phenomena. Mov. Disord. 19(8), 871–884 (2004).
   PubMed Web of Science ®Google Scholar
• Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41, 202–205 (1991).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the onset mode in Parkinsonism. Neurology 43, 829–830 (1993).
   PubMed Web of Science ®Google Scholar
• Sitte H, Fenton ME, Pifl C, Rajput AH, Hornykiewicz O. Globus pallidus (GP) dopamine (DA) metabolism and Parkinson’s disease (PD) manifestations. Neurology 52(Suppl. 2), A213 (1999).
   Google Scholar
• del Olmo MF, Cudeiro J. Temporal variability of gait in Parkinson’s disease: effects of a rehabilitation programme based on rhythmic sound cues. Parkinsonism Relat. Disord. 11, 25–33 (2005).
   PubMed Web of Science ®Google Scholar
• Cubo E, Moore CG, Leurgans S, Goetz CG. Wheeled and standard walkers in Parkinson’s disease patients with gait freezing. Parkinsonism Relat. Disord. 10, 9–14 (2003).
   PubMed Web of Science ®Google Scholar